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Background: Notch1 transmembrane receptor is activated through ligand-binding- triggered proteolytic cleavages
and, upon release, the intracellular domain (N1-ICD) translocates into the nucleus and modulates target gene
transcriptions. Notch activation has been implicated in tumorigenesis in an increasing number of human malignancies
including non-small cell lung cancer (NSCLC). However, Notch1 in distinct expression patterns and activation status
with tumor progression remains to be defined in NSCLC.
Methods: Notch1 and activated Notch1, N1-ICD, were examined by immunohistochemistry in 58 cases of stage I to
IV NSCLC tumors. Association between Notch1 or N1-ICD expression and clinicopathological factors was assessed via
correlation coefficient r statistics. P-values are two-sided.
Results: Detectable tumor Notch1, predominantly localized to the membrane and cytoplasm, was observed in 29
cases (50%, 95% Blyth-Still-Casella confidence interval 37 – 63%). It was negatively associated with stage (r = - 0.43,
P < 0.001) and nodal status (r = - 0.33, P = 0.01), but not tumor size. In contrast, nuclear N1-ICD expression level was
low and found in 12% of NSCLC patients, neither significantly associated with stage nor nodal status. Upon Notch1
activation in vitro, a mostly extra-nuclear staining was substantially turned into the nuclear signal in cancer cells.
Conclusions: Notch1 in the largely inactivated phenotype is inversely associated with clinical stage progression in
NSCLC. Notch1, rather than activated N1-ICD, may be a context-dependent restrictive factor to nodal metastasis.
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Lung cancer is the leading cause of cancer-related
mortality in men and women in the United States and
Europe [1]. Approximately 85% of all lung cancers are
non-small cell lung cancer (NSCLC), which includes
squamous cell carcinoma, adenocarcinoma and large
cell carcinoma (LCLC). The Notch signaling pathway
is a highly evolutionally conserved signal transduction
network that is critical for cell fate specification in a
context-dependent manner during and after development
in various organ tissues [2,3]. Notch signaling is frequently
deregulated in human hematological malignancies [4,5]
and solid tumors including NSCLC, through gene muta-
tions and aberrant expression of Notch receptors [6,7].* Correspondence: Sherry.Yang@nih.gov
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unless otherwise stated.Specifically, Notch signaling maintains a balance between
cell proliferation and apoptosis and has been shown to be
oncogenic or tumor-suppressive depending on the cancer
types; it can be both oncogenic and tumor-suppressive
within one cancer type such as in B-cell malignancies
[8]. Activated Notch1, in co-operation with Myc or
through regulation of expression of epidermal growth
factor receptor (EGFR), was implicated in the tumori-
genesis, proliferation and survival of NSCLC models in
preclinical studies [9,10]. Moreover, hypoxia via HIF1α
stabilizes and activates Notch1 in lung adenocarcinomas.
In turn, Notch1 activates the IGF-1R pathway, promoting
cancer cell survival under hypoxia [11,12]. Inhibition of
ADAM-17— a critical step of ligand-dependent activation
of Notch signaling led to substantial cell death and
reduced tumorigenesis in NSCLC cell lines and xeno-
graft tumor models. Activated Notch1 was associated
with poor survival in NSCLC patients without p53l. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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in tumorigenesis and tumor cell survival, association of
Notch1 expression levels and patterns with tumor pro-
gression in terms of tumor size and metastasis remains
to be delineated.
The Notch receptors are non-covalently bound hetero-
dimeric proteins, consisting of a large N-terminal extra-
cellular portion (NEC) featuring multiple EGF-like repeats
and the Notch transmembrane domain (NTM), which
includes an extracellular stub, transmembrane segment
and intracellular domain (NICD) [14,15]. The NICD,
upon sequential cleavages of NTM by ADAM10 or 17 and
gamma-secretase, is released from the plasma membrane
and translocates into the nucleus, where it activates target
gene transcriptions. In addition, the EGF repeats in the
NEC is calcium-dependent. Calcium depletion by EDTA
can destabilize NEC and lead to its dissociation from NTM,
activating the signaling of some of the Notch receptors
such as Notch1 and 2 [16].
Agents targeting the Notch pathway including γ-
secretase inhibitors (GSIs) and monoclonal antibodies
(mAbs) to Notch ligands and Notch receptors are currently
in early clinical development across a range of advanced
human malignancies. GSIs have numerous possible targets,
but their anti-neoplastic effects are thought to be due
mostly to Notch inhibition, primarily Notch1, observed
by several studies [15,17,18]. However, single-agent
antitumor activity of Notch inhibitors, as determined
by radiologic responses, was observed in only about 3%
of patients treated with a Notch pathway inhibitor
according to available clinical trial data [15]. Unexpect-
edly, clinical activity has not been observed in patients
whose tumors harbor Notch1 mutations thus far [19,20].
Moreover, systemic Notch inhibitor administration causes
significant toxicities with dose limiting gastrointestinal
adverse events (goblet cell metaplasia and secretory
diarrhea) [15].
Given the current clinical challenges and specific
features of the Notch signaling, it is important to
characterize expression levels and patterns in associ-
ation with activated or inactivated Notch1, and in turn
elucidate the target status quo for therapeutic interven-
tion. In this study, we examined Notch1expression in
NSCLC, and identified those tumors with abundant
Notch1 as well as activated Notch1, N1-ICD, at γ-
secretase cleavage site (N1-ICD-V1754). Notch1 and
N1-ICD-V1754 expression patterns were characterized
in cancer cell lines via modulation using EDTA and in
human NSCLC tumors. Particularly, this investigation
tested the hypothesis that inactivated Notch1 may play
a suppressive role in tumor progression through defining
Notch1 or N1-ICD-V1754 status in relation to clinico-
pathological factors such as tumor differentiation, nodal
status and clinical stage.Results
Modulation of Notch1 expression patterns following
activation by EDTA in cancer cells, and validation of
antibodies
To characterize Notch1 expression patterns, NSCLC and
breast cancer cells were treated with EDTA to activate
Notch1. With and without EDTA exposure, EP1238Y
antibody identified Notch1 protein of ~125 kDa, corre-
sponding to the approximate size of NTM of Notch1
(Figure 1A); D3B8 antibody detected N1-ICD-V1754
of ~110 kDa in NSCLC NCI-H23, NCI-H522 and breast
cancer MCF-7 cells after EDTA treatment. Immunocyto-
chemistry analysis revealed that Notch1 was mainly bound
to the membrane and cytoplasm, and upon EDTA treat-
ment, N1-ICD-V1754 was rapidly induced and translo-
cated to the nucleus in NCI-H23 cells (Figure 1B). These
results indicate specific modulation of Notch1 expression
patterns upon Notch1 activation by EDTA, switching a
mostly membranous/cytoplasmic staining to the dark-
brown signal in the nucleus in NSCLC cells expressing
Notch1. In addition, specificity and utility of the two
antibodies were validated for use in paraffin-embedded
sections. Further, the cell adhesion molecule E-cadherin
was decreased in MCF-7 and NCI-H23 cells (Figure 1A).
To ascertain and extend the findings, NCI-H358 and
NCI-H322M NSCLC cells were also subjected to EDTA
treatment. As expected, N1-ICD-V1754 was markedly
induced in these cells that express Notch1 (Figure 2A).
The reduction of E-cadherin by EDTA treatment was also
studied further with these two cell lines. It was again
noted that appearance of N1-ICD-V1754 was coupled
with a significant reduction in E-cadherin expression by
both Western blot and immunocytochemistry (Figure 2A
and B). Treatment with EDTA in the presence of
RO4929097 prevented Notch1 activation and partially
rescued E-cadherin from the decrease (Figure 2A).
Expression of Notch1 and N1-ICD-V1754 in human NSCLC
All levels of tumor Notch1expression were found in 29 of
the 58 NSCLC cases (50%, 95% CI 37% – 63%), with 8
cases (14%) exhibiting strong staining. These included 5 of
the 35 cases of squamous cell carcinomas, 2/19 adenocar-
cinomas, and 1/4 undifferentiated or large cell undifferenti-
ated carcinomas (Table 1; Figure 3). Notch1expression was
not statistically different between adenocarcinomas and
squamous cell carcinomas (P = 0.57; Table 1). Similar to the
expression pattern observed in cancer cells, membranous/
cytoplasmic/nuclear Notch1, with an extra-nuclear staining
as the major signal, was observed in NSCLC tumors. In
addition, it was high levels of Notch1 expression, 6 out of 8,
which were coupled to heterogeneous N1-ICD-V1754
expression (Figure 3).
Expression of N1-ICD-V1754 was exclusively nuclear
and detected in 7 of the 58 cases (12%, 95% CI 6-22%).
Figure 1 Expression of Notch1, N1-ICD-V1754 and E-cadherin by Western blot and immunocytochemistry in cancer cells. Western blot
analysis demonstrates specific bands of the respective proteins of Notch1, N1-ICD-V1754 and E-cadherin in MCF-7, NCI-H23 and NCI-H522 cells
(A). Notch1 (a, c) and N1-ICD-V1754 (b, d) expression in formalin-fixed and paraffin-embedded NCI-H23 cells (B). Magnifications x600.
Nguyen et al. Journal of Hematology & Oncology  (2015) 8:9 Page 3 of 8The seven were all from 29 Notch1-positive cases, and
none from Notch1-negative ones. Among those, the
expression levels were low in 6 cases and intermediate
in one sample, relative to NCI-H23 cells treated with
EDTA. In the context of heterogeneous Notch1 activation,
we observed a heterogeneous Ki67 labeling/tumor cell
proliferation (Figure 3).
Association between Notch1 or N1-ICD-V1754 and
clinicopathological covariates in NSCLC
Analysis of disease-related clinicopathological parameters
showed neither a significant association between Notch1
expression and demographics including age and sex, nor a
correlation between Notch1 and tumor grade or tumor
size (Table 2). However, there was a significant negativeassociation between Notch1 and clinical stage (r = - 0.43;
P < 0.001) or between Notch1 and nodal status (r = - 0.33;
P = 0.01). In contrast, N1-ICD-V1754 was not significantly
associated with stage (r = - 0.06; P = 0.65) and nodal status
(r = - 0.09; P = 0.50).
Discussion
Our data demonstrate that all levels of Notch1are detected
in 50% of stage I to IV NSCLC tumors, and it is predomin-
antly localized in the cell membrane and cytoplasm. Notch1
is largely inactivated in NSCLC as only a small fraction of
NSCLC samples heterogeneously express low levels of
N1-ICD-V1754 [21]. Immunocytochemistry results clearly
show that Notch1 translocation from the cell membrane
to the nucleus upon activation by EDTA treatment,
Figure 2 Confirmation of expression of Notch1, N1-ICD-V1754 and E-cadherin in additional NSCLC cells. Expression of Notch1, N1-ICD-V1754
and E-cadherin were analyzed using Western blot in NSCLC NCI-H358 and NCI-H322M cells (A). E-cadherin expression was examined by
immunohistochemistry in NSCLC NCI-H358 and NCI H322M cell lines (B). Magnifications x600.
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in NSCLC and breast cancer cells [15,16,22]. EDTA treat-
ment could elicit a degree of Notch1 activation comparable
to that resulted from Notch ligand Delta-1 exposure [16].






Squamous cell carcinoma 35
Adenocarcinoma 19
Undifferentiated/large cell carcinoma P value† 4
Squamous cell vs. adenocarcinoma
*Blythe-Still-Casella 95% confidence interval (CI).
†Comparison of percent positivity by Fisher’s Exact Test; 2-sided P value.during EDTA treatment abolishes Notch1 activation, sug-
gesting that Notch1 activation mediated by EDTA is
gamma-secretase-dependent in NSCLC cells.
Importantly, the inactivated Notch1 configuration in
NSCLC is inversely associated with locoregional noderession High expression
of positive % (95% CI)* No. of positive % (95% CI)
29 50 (37 – 63) 8 14 (6 - 25)
19 54 (37 - 71) 5 14 (6 - 29)
8 42 (22 - 66) 2 11 (2 - 32)
3 75 (25 - 99) 1 25 (1 - 75)
0.57 1.0
Figure 3 Representative staining patterns of Notch1, N1-ICD-V1754 and heterogeneous tumor cell proliferation (Ki67) in NSCLC tumor
tissues. Notch1, N1-ICD-V1754 and Ki67 in a case of undifferentiated carcinoma of the lung, showing high level of membranous/cytoplasmic/nuclear
Notch1 expression (A2), nuclear N1-ICD-V1754 (A3), and Ki67 labeling (A4). Notch1, N1-ICD-V1754 and Ki67 in a case of squamous cell carcinoma of
the lung, displaying high level of cytoplasmic/membranous/nuclear Notch1staining (B2), heterogeneous N1-ICD-V1754 (B3), and Ki67 proliferation
(B4). Notch1, N1-ICD-V1754 and Ki67 in a case of adenocarcinoma of the lung, exhibiting cytoplasmic/membranous Notch1 signal (C2) and some
nuclear N1-ICD-V1754 staining on the right (C3), and Ki67 expression (C4). HE staining of undifferentiated carcinoma, squamous cell carcinoma and
adenocarcinoma of the lung (A1, B1, and C1). Magnifications x200.
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tumor size. Thus, the negative association between
Notch1phenotype and clinical stage progression is likely
driven by nodal status. The findings support our hypothesis
that inactivated Notch1 may serve as a context-dependent
restrictive factor of tumor cells to local-regional spread.
The scenarios that inactivated Notch1 is protective against
nodal spread could be explained as follows. First, as the
single-pass heterodimeric transmembrane receptor and/
or in couple with Notch ligands on the cell surface,
Notch1 mediates cell-to-cell interactions in adjacent cellsTable 2 Association of Notch1with clinicopathological
variables in NSCLC
Variable No. of cases Correlation co-efficient, r P value*
Age 58 0.02 0.91
Sex 58 0.15 0.25
Grade 45 -0.07 0.66
Tumor size 57 -0.04 0.76
Nodal status 56 -0.33 0.01
Stage 57 -0.43 ≤0.001
*By correlation coefficient r statistics, two sided P value.and may therefore physically limits the migration of
tumors cells [14]. Secondly, other lines of experimental
evidence showed that without Notch1 activation, the
adherens junctions complex containing E-cadherin is
intact, which suppresses tumor cell migration and metas-
tasis [22,23]. In NSCLC A549, NCI-H1650 and NCI-H596
cells, E-cadherin expression was decreased after transfec-
tion with a N1-ICD vector [24]. Notch1 down-regulated
E-cadherin through upregulation of the snail family of
transcriptional factors in these cell lines [24]. The reduc-
tion in E-cadherin by EDTA treatment can be somewhat
rescued by RO4929097 in NCI-H358 and NCI-H322M
cells. The data suggest that Notch1 activation is in part
responsible for reducing E-cadherin. By contrast, activated
Notch1 is not negatively associated with nodal metastasis.
Rather, heterogeneous N1-ICD-V1754 expression is asso-
ciated with heterogeneous tumor cell proliferation in
NSCLC. In agreement with our results, a study found that
Notch1 expression was inversely correlated with stage,
despite lack of correlative data on nodal metastasis, in 395
NSCLC tumor samples by immunohistochemistry using a
semi-quantitative scoring method [25]. Moreover, Notch1
expression predicted not only less progressive disease but
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patients [26] Taken together, Notch1 plays distinct roles
depending on its activation status in patients with all
stages of NSCLC from I to IV.
Interestingly in this study, we found that Notch1and
N1-ICD-V1754 are expressed in undifferentiated carcin-
omas of the lung, which has not been described previously
[27]. Notch1and N1-ICD-V1754 were also found highly
expressed in a case of undifferentiated carcinoma of the
ovary [28]. Undifferentiated carcinoma is an epithelial
malignancy that lacks morphologic or functional indica-
tors of its embryonic origin, capable of deriving from
many organ sites including bladder, cervix, colon, esopha-
gus, larynx, pancreas, salivary glands, thyroid and uterine,
besides lung and ovary [29,30]. Given the implication of
the Notch pathway signaling in early development, Notch
signaling may be of significance in the pathogenesis of
undifferentiated carcinoma. Additional studies should
investigate the role of Notch1 signaling in the patho-
genesis of undifferentiated carcinomas.
Conclusions
Expression of membranous and cytoplasmic Notch1ex-
pression is common, in contrast to the activated Notch1
in the nucleus, in human NSCLC [9,10]. Such pattern of
expression or inactivated Notch1 may serve as a marker
of low-metastatic propensity while high levels of or
activated Notch1 a more pertinent therapeutic target in
NSCLC or advanced NSCLC. We anticipate clinical
validation of Notch1 and N1-ICD-V1754 expression levels
and patterns for the purpose of evaluation of efficacy,
ultimately patient stratification, and as a pharmaco-
dynamics biomarker to document inhibition of Notch
cleavage after treatment with the Notch pathway inhibi-
tors in clinical trials.
Methods
Cells, cell culture, and EDTA and GSI treatment
The NSCLC cell lines NCI-H23 (adenocarcinoma), NCI-
H522 (adenocarcinoma), NCI-H322M (adenocarcinoma)
and NCI-H358 (adenocarcinoma) were obtained from
the Tumor/Cell Line Repository, Division of Cancer
Treatment and Diagnosis, National Cancer Institute.
MCF-7 breast cancer cells were obtained from ATCC
(Rockville, MD). Exponentially growing cells in 10% fetal
bovine serum RPMI media at ~ 80% confluence were
washed with serum-free RPMI. After washing, cells were
treated with EDTA at a concentration of 0.53 mM or
serum-free RPMI for 15 minutes and subsequently sub-
jected to either formalin fixation and paraffin-embedding
or cell lysis for lysates collection. Additionally, NCI-H358
and NCI-H322M cells were treated with 5 μM of a GSI
RO4929097 (Selleck Chemicals, Boston, MA), for 10 min
before adding EDTA solution containing 5 μM ofRO4929097. After 15 min, lysates were collected or cells
were fixed with 10% neutral buffered formalin before
paraffin embedding.
Western blot
Equal numbers of cells were lysed in Laemmli sample
buffer and proteins in the lysates were separated by electro-
phoresis [31]. After protein separation and transferring,
nitrocellulose filters were probed with monoclonal anti-
bodies to Notch1 (clone EP1238Y, Abcam Inc., Cambridge,
MA) and cleaved Notch1, N1-ICD-V1754 (clone D3B8,
Cell Signaling Technology Inc., Danvers, MA) in dilutions
of 1 to 5000 and 1 to 500, respectively. The Notch1 anti-
body recognizes the cytoplasmic portion of human Notch1
receptor. The cleaved Notch1 antibody specifically recog-
nizes an epitope of Notch1 intracellular domain when
cleaved at the protein sequence between G1753 and V1754
for human Notch1 (N1-ICD-V1754) or G1743 and V1744
for mouse and rat [16,32]. E-cadherin was detected by a
monoclonal antibody against E-cadherin (clone HECD-1,
Invitrogen Corp., Camarillo, CA) in 1 to 500 dilution and
incubated for 1 hour at 37°C. ß-actin was probed with
mAb at a dilution of 1: 10,000 as loading control (Sigma,
St. Louis, MI). Reactive proteins were revealed using
an enhanced chemiluminescence (Pierce Chemical Co.,
Rockford, Illinois, USA).
Human lung cancer tissue microarray specimens
Lung cancer tissue microarrays and clinicopathological
data were obtained from Cybrdi, Incorporation (Rockville,
MD), and FOLIO Biosciences (Powell, OH). Approval of
the biomarker study on de-identified human tissues was
obtained from the Office of Human Research Protections,
National Institutes of Health, Bethesda, Maryland. Tumor
presence and histology were confirmed on HE stained
sections.
Immunohistochemistry or immunocytochemistry and
quantitative analysis
Immunohistochemistry method on formalin-fixed and
paraffin-embedded sections has been described previously
[33,34]. In brief, after incubation of the primary antibodies
to Notch1 and cleaved Notch1 in dilutions of 1: 200 and
1: 20 or antibody to E-cadherin in 1:100 dilution or anti-
body to Ki67 in 1: 200 dilution (clone MIB-1, DAKO) for
1 hour, binding of the antibodies to their antigen binding
sites in sections was amplified using Vectastain Elite
avidin-biotin-peroxidase complex kits (Vector Laborator-
ies, Burlingame, CA). The antigen-antibody reaction sites
were visualized using 3,3-diaminobenzidine for 7 min and,
subsequently, sections were counterstained with Mayer’s
hematoxylin. Paraffin-embedded NCI-H23 cells or MCF-7
cells treated with and without EDTA described above were
used as controls; negative controls were performed using
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bodies used. Areas of tumor staining on each tissue core
were analyzed with assistance of a digital imaging system
(DAKO, Carpinteria, CA) by reporting intensity and per-
centage of staining. Staining Index (SI) for Notch1 or N1-
ICD-V1754 was calculated as the percentage multiplied by
the intensity of staining (after subtracting the tissue read-
out of the corresponding negative control) divided by 100
(SI = intensity x percentage/100) [34]. It was defined as
negative if SIs were < 2, and positive if the SIs were ≥ 2. As
for defining the levels of expression, it was considered as
the low level if SIs were ≥ 2 and <15 (1+ by manual
scoring of intensity), as the moderate level if SIs were ≥ 15
and < 30 (2+), and as the high level if SIs were ≥ 30 (3+).
Statistical analysis
The correlation between Notch1 or N1-ICD-1754 and age
was analyzed using the Pearson’s correlation coefficient
r statistic. All other correlations between Notch1 or
N1-ICD-1754 and sex, grade, tumor size, nodal status
or clinical stage were assessed by the Spearman’s rank
order correlation coefficient. The two-sided P-values
were calculated by means of Fisher transformation, and
P values < 0.05 were considered statistically significant.
Comparison of Notch1 percent positivity between squa-
mous and adenocarcinoma was assessed by Fisher’s Exact
test, two-sided P-value.
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